Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis

Blood Cancer J. 2025 Dec 6;15(1):212. doi: 10.1038/s41408-025-01413-7.ABSTRACTFrontline therapy for transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) has advanced with anti-CD38 monoclonal antibody (mAb)-based regimens. Although quadruplet combinations incorporating daratumumab and is

J João Tadeu Damian Souto Filho

Androgen deprivation therapy with apalutamide in the treatment of metastatic castration-sensitive prostate cancer: the systematic review of its effectiveness and applicability for Asian men in the targeted investigational treatment analysis of novel anti-androgen (TITAN) trial

Int Urol Nephrol. 2025 Dec 6. doi: 10.1007/s11255-025-04943-y. Online ahead of print.ABSTRACTBACKGROUND: The TITAN trial established survival benefits of adding apalutamide to androgen deprivation therapy (ADT) in metastatic castration‑sensitive prostate cancer (mCSPC). Whether efficacy and safety a

F Fan Yang

Proteome-wide association study of prostate cancer risk across populations

Nat Commun. 2025 Dec 6. doi: 10.1038/s41467-025-66250-5. Online ahead of print.ABSTRACTThere is insufficient understanding of the molecular basis of prostate cancer (PCa) across different populations. We perform a large-scale proteome-wide association study (PWAS) to identify proteins with genetical

H Hua Zhong